ESMO-BC 2024 - ESMO Breast Cancer Annual Congress
May 15 - May 17, 2024 | BerlinGermany
LARVOL is not affiliated with ESMO Breast Cancer Annual Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 96 abstracts linked to Trials
180O - IMpassion132 double-blind randomised phase III trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)
109O - Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies
LBA2 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01
160P - Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype
183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): Second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
267MO - Pooled analysis of trastuzumab deruxtecan (T-DXd) retreatment (RTx) after recovery from grade (Gr) 1 interstitial lung disease/pneumonitis (ILD)
1MO - HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
266O - Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study
181O - Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
184MO - First-in-human phase I/IIa study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): Safety and efficacy update
182MO - Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated overall survival (OS) results of the randomized phase III DESTINY-breast (DB-)02 study
269MO - The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer: Results of the multinational randomized PREFERABLE-EFFECT trial
3MO - Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE
112MO - Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial
179O - Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trial